

# Pharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2023

<https://marketpublishers.com/r/P69032B56911EN.html>

Date: August 2023

Pages: 85

Price: US\$ 2,950.00 (Single User License)

ID: P69032B56911EN

## Abstracts

### Highlights

The global Pharmacogenomics Technology (Theranostics & CDx) market is projected to reach US\$ million by 2029 from an estimated US\$ million in 2023, at a CAGR of % during 2024 and 2029.

North American market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from \$ million in 2023 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

Asia-Pacific market for Pharmacogenomics Technology (Theranostics & CDx) is estimated to increase from \$ million in 2023 to reach \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

The major global companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, Roche, Agilent, Abbott, Thermofisher, Qiagen, Guardant Health, MGI Tech Co., Ltd. and Amoydx Biology, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

The global market for Pharmacogenomics Technology (Theranostics & CDx) in Tumor is estimated to increase from \$ million in 2023 to \$ million by 2029, at a CAGR of % during the forecast period of 2024 through 2029.

Considering the economic change due to COVID-19 and Russia-Ukraine War Influence, Instrument, which accounted for % of the global market of Pharmacogenomics Technology (Theranostics & CDx) in 2022, is expected to reach million US\$ by 2029,

growing at a revised CAGR of % from 2024 to 2029.

## Report Scope

This report aims to provide a comprehensive presentation of the global market for Pharmacogenomics Technology (Theranostics & CDx), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pharmacogenomics Technology (Theranostics & CDx).

The Pharmacogenomics Technology (Theranostics & CDx) market size, estimations, and forecasts are provided in terms of and revenue (\$ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Pharmacogenomics Technology (Theranostics & CDx) market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Pharmacogenomics Technology (Theranostics & CDx) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

## Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue by companies for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research

report include:

Illumina

Roche

Agilent

Abbott

ThermoFisher

Qiagen

Guardant Health

MGI Tech Co., Ltd.

Amoydx Biology

Genomics

## Product Type Insights

Global markets are presented by Pharmacogenomics Technology (Theranostics & CDx) type, along with growth forecasts through 2029. Estimates on revenue are based on the price in the supply chain at which the Pharmacogenomics Technology (Theranostics & CDx) are procured by the companies.

This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows revenue data by type, and during the historical period (2018-2023) and forecast period (2024-2029).

## Pharmacogenomics Technology (Theranostics & CDx) segment by Type

Instrument

Reagents and Consumables

Others

### Application Insights

This report has provided the market size (revenue data) by application, during the historical period (2018-2023) and forecast period (2024-2029).

This report also outlines the market trends of each segment and consumer behaviors impacting the Pharmacogenomics Technology (Theranostics & CDx) market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Pharmacogenomics Technology (Theranostics & CDx) market.

### Pharmacogenomics Technology (Theranostics & CDx) Segment by Application

Tumor

Diabetes

Mental Diseases

Cardiovascular Diseases

Others

### Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue data of each region and country for the period 2018-2029.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis

of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2022 because of the base year, with estimates for 2023 and forecast revenue for 2029.

## North America

United States

Canada

## Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

## Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

## Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

## COVID-19 and Russia-Ukraine War Influence Analysis

The readers in the section will understand how the Pharmacogenomics Technology (Theranostics & CDx) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the

years to come.

## Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacogenomics Technology (Theranostics & CDx) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

This report will help stakeholders to understand the global industry status and trends of Pharmacogenomics Technology (Theranostics & CDx) and provides them with information on key market drivers, restraints, challenges, and opportunities.

This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Pharmacogenomics Technology (Theranostics & CDx) industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacogenomics Technology (Theranostics & CDx).

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

## Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Pharmacogenomics Technology (Theranostics & CDx) companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.



## Contents

### 1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
  - 1.5.1 Secondary Sources
  - 1.5.2 Primary Sources

### 2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Pharmacogenomics Technology (Theranostics & CDx) by Type
  - 2.2.1 Market Value Comparison by Type (2018 VS 2022 VS 2029)
    - 1.2.2 Instrument
    - 1.2.3 Reagents and Consumables
    - 1.2.4 Others
- 2.3 Pharmacogenomics Technology (Theranostics & CDx) by Application
  - 2.3.1 Market Value Comparison by Application (2018 VS 2022 VS 2029)
  - 2.3.2 Tumor
  - 2.3.3 Diabetes
  - 2.3.4 Mental Diseases
  - 2.3.5 Cardiovascular Diseases
  - 2.3.6 Others
- 2.4 Assumptions and Limitations

### 3 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY TYPE

- 3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Type (2018-2023)
- 3.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2023-2028)

### 4 PHARMACOGENOMICS TECHNOLOGY (THERANOSTICS & CDX) BREAKDOWN DATA BY APPLICATION

4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Application (2018-2023)

4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2018-2023)

## **5 GLOBAL GROWTH TRENDS**

5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Perspective (2018-2029)

5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Growth Trends by Region

5.2.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2018 VS 2022 VS 2029

5.2.2 Pharmacogenomics Technology (Theranostics & CDx) Historic Market Size by Region (2018-2023)

5.2.3 Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029)

5.3 Pharmacogenomics Technology (Theranostics & CDx) Market Dynamics

5.3.1 Pharmacogenomics Technology (Theranostics & CDx) Industry Trends

5.3.2 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers

5.3.3 Pharmacogenomics Technology (Theranostics & CDx) Market Challenges

5.3.4 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints

## **6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS**

6.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue

6.1.1 Global Top Pharmacogenomics Technology (Theranostics & CDx) Players by Revenue (2018-2023)

6.1.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Players (2018-2023)

6.2 Global Pharmacogenomics Technology (Theranostics & CDx) Industry Players Ranking, 2021 VS 2022 VS 2023

6.3 Global Key Players of Pharmacogenomics Technology (Theranostics & CDx) Head office and Area Served

6.4 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Product Type & Application

6.5 Global Pharmacogenomics Technology (Theranostics & CDx) Players, Date of

Enter into This Industry

6.6 Global Pharmacogenomics Technology (Theranostics & CDx) Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

## **7 NORTH AMERICA**

7.1 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)

7.2 North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)

7.4 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)

7.5 United States

7.6 Canada

## **8 EUROPE**

8.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)

8.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029

8.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)

8.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)

7.4 Germany

7.5 France

7.6 U.K.

7.7 Italy

7.8 Russia

7.9 Nordic Countries

## **9 ASIA-PACIFIC**

9.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)

9.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth

Rate by Country: 2018 VS 2022 VS 2029

9.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)

9.4 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)

8.4 China

8.5 Japan

8.6 South Korea

8.7 Southeast Asia

8.8 India

8.9 Australia

## **10 LATIN AMERICA**

10.1 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)

10.2 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)

10.4 Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)

9.4 Mexico

9.5 Brazil

## **11 MIDDLE EAST & AFRICA**

11.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size (2018-2029)

11.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029

11.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023)

11.4 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029)

10.4 Turkey

10.5 Saudi Arabia

10.6 UAE

## 12 PLAYERS PROFILED

### 11.1 Illumina

11.1.1 Illumina Company Detail

11.1.2 Illumina Business Overview

11.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Introduction

11.1.4 Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)

11.1.5 Illumina Recent Development

### 11.2 Roche

11.2.1 Roche Company Detail

11.2.2 Roche Business Overview

11.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Introduction

11.2.4 Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)

11.2.5 Roche Recent Development

### 11.3 Agilent

11.3.1 Agilent Company Detail

11.3.2 Agilent Business Overview

11.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Introduction

11.3.4 Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)

11.3.5 Agilent Recent Development

### 11.4 Abbott

11.4.1 Abbott Company Detail

11.4.2 Abbott Business Overview

11.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Introduction

11.4.4 Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)

11.4.5 Abbott Recent Development

### 11.5 Thermofisher

11.5.1 Thermofisher Company Detail

11.5.2 Thermofisher Business Overview

11.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx)

Introduction

11.5.4 Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)

11.5.5 Thermofisher Recent Development

### 11.6 Qiagen

- 11.6.1 Qiagen Company Detail
- 11.6.2 Qiagen Business Overview
- 11.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Introduction
- 11.6.4 Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
- 11.6.5 Qiagen Recent Development
- 11.7 Guardant Health
  - 11.7.1 Guardant Health Company Detail
  - 11.7.2 Guardant Health Business Overview
  - 11.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Introduction
  - 11.7.4 Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
  - 11.7.5 Guardant Health Recent Development
- 11.8 MGI Tech Co., Ltd.
  - 11.8.1 MGI Tech Co., Ltd. Company Detail
  - 11.8.2 MGI Tech Co., Ltd. Business Overview
  - 11.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Introduction
  - 11.8.4 MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
  - 11.8.5 MGI Tech Co., Ltd. Recent Development
- 11.9 Amoydx Biology
  - 11.9.1 Amoydx Biology Company Detail
  - 11.9.2 Amoydx Biology Business Overview
  - 11.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Introduction
  - 11.9.4 Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
  - 11.9.5 Amoydx Biology Recent Development
- 11.10 Genomics
  - 11.10.1 Genomics Company Detail
  - 11.10.2 Genomics Business Overview
  - 11.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Introduction
  - 11.10.4 Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022)
  - 11.10.5 Genomics Recent Development

## **13 REPORT CONCLUSION**

## 14 DISCLAIMER

## List Of Tables

### LIST OF TABLES

Table 1. Secondary Sources

Table 2. Primary Sources

Table 3. Market Value Comparison by Type (2018 VS 2022 VS 2029) & (US\$ Million)

Table 4. Market Value Comparison by Application (2018 VS 2022 VS 2029) & (US\$ Million)

Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type (2018-2023) & (US\$ Million)

Table 6. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2018-2023)

Table 7. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Type (2024-2029) & (US\$ Million)

Table 8. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type (2024-2029)

Table 9. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application (2018-2023) & (US\$ Million)

Table 10. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2018-2023)

Table 11. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Application (2024-2029) & (US\$ Million)

Table 12. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2024-2029)

Table 13. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (US\$ Million): 2018 VS 2022 VS 2029

Table 14. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region (2018-2023) & (US\$ Million)

Table 15. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2018-2023)

Table 16. Global Pharmacogenomics Technology (Theranostics & CDx) Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 17. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share by Region (2024-2029)

Table 18. Pharmacogenomics Technology (Theranostics & CDx) Market Trends

Table 19. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers

Table 20. Pharmacogenomics Technology (Theranostics & CDx) Market Challenges

Table 21. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints



- Table 22. Global Top Pharmacogenomics Technology (Theranostics & CDx) Manufacturers by Revenue (US\$ Million) & (2018-2023)
- Table 23. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Manufacturers (2018-2023)
- Table 24. Global Pharmacogenomics Technology (Theranostics & CDx) Industry Manufacturers Ranking, 2021 VS 2022 VS 2023
- Table 25. Global Key Players of Pharmacogenomics Technology (Theranostics & CDx), Headquarters and Area Served
- Table 26. Global Pharmacogenomics Technology (Theranostics & CDx) Manufacturers, Product Type & Application
- Table 27. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 28. Global Pharmacogenomics Technology (Theranostics & CDx) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2022)
- Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
- Table 30. North America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 31. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US\$ Million)
- Table 32. North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US\$ Million)
- Table 33. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 34. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US\$ Million)
- Table 35. Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US\$ Million)
- Table 36. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 37. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US\$ Million)
- Table 38. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US\$ Million)
- Table 39. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)
- Table 40. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US\$ Million)
- Table 41. Latin America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US\$ Million)
- Table 42. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx)

Market Growth Rate by Country: 2018 VS 2022 VS 2029 (US\$ Million)

Table 43. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Illumina Company Detail

Table 46. Illumina Business Overview

Table 47. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product

Table 48. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 49. Illumina Recent Development

Table 50. Roche Company Detail

Table 51. Roche Business Overview

Table 52. Roche Pharmacogenomics Technology (Theranostics & CDx) Product

Table 53. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 54. Roche Recent Development

Table 55. Agilent Company Detail

Table 56. Agilent Business Overview

Table 57. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product

Table 58. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 59. Agilent Recent Development

Table 60. Abbott Company Detail

Table 61. Abbott Business Overview

Table 62. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product

Table 63. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 64. Abbott Recent Development

Table 65. Thermofisher Company Detail

Table 66. Thermofisher Business Overview

Table 67. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product

Table 68. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 69. Thermofisher Recent Development

Table 70. Qiagen Company Detail

Table 71. Qiagen Business Overview

Table 72. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product

Table 73. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx)

Business (2017-2022) & (US\$ Million)

Table 74. Qiagen Recent Development

Table 75. Guardant Health Company Detail

Table 76. Guardant Health Business Overview

Table 77. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product

Table 78. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 79. Guardant Health Recent Development

Table 80. MGI Tech Co., Ltd. Company Detail

Table 81. MGI Tech Co., Ltd. Business Overview

Table 82. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product

Table 83. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 84. MGI Tech Co., Ltd. Recent Development

Table 85. Amoydx Biology Company Detail

Table 86. Amoydx Biology Business Overview

Table 87. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product

Table 88. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 89. Amoydx Biology Recent Development

Table 90. Genomics Company Detail

Table 91. Genomics Business Overview

Table 92. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product

Table 93. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2017-2022) & (US\$ Million)

Table 94. Genomics Recent Development

Table 95. Illumina Company Information

Table 96. Illumina Business Overview

Table 97. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 98. Illumina Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 99. Illumina Recent Development

Table 100. Roche Company Information

Table 101. Roche Business Overview

Table 102. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 103. Roche Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 104. Roche Recent Development

Table 105. Agilent Company Information

Table 106. Agilent Business Overview

Table 107. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 108. Agilent Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 109. Agilent Recent Development

Table 110. Abbott Company Information

Table 111. Abbott Business Overview

Table 112. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 113. Abbott Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 114. Abbott Recent Development

Table 115. Thermofisher Company Information

Table 116. Thermofisher Business Overview

Table 117. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 118. Thermofisher Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 119. Thermofisher Recent Development

Table 120. Qiagen Company Information

Table 121. Qiagen Business Overview

Table 122. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 123. Qiagen Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 124. Qiagen Recent Development

Table 125. Guardant Health Company Information

Table 126. Guardant Health Business Overview

Table 127. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 128. Guardant Health Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 129. Guardant Health Recent Development

Table 130. MGI Tech Co., Ltd. Company Information

Table 131. MGI Tech Co., Ltd. Business Overview

Table 132. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 133. MGI Tech Co., Ltd. Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 134. MGI Tech Co., Ltd. Recent Development

Table 135. Amoydx Biology Company Information

Table 136. Amoydx Biology Business Overview

Table 137. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 138. Amoydx Biology Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

Table 139. Amoydx Biology Recent Development

Table 140. Genomics Company Information

Table 141. Genomics Business Overview

Table 142. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million)

Table 143. Genomics Revenue in Pharmacogenomics Technology (Theranostics & CDx) Business (2018-2023) & (US\$ Million) Portfolio

## I would like to order

Product name: Pharmacogenomics Technology (Theranostics & CDx) Industry Research Report 2023

Product link: <https://marketpublishers.com/r/P69032B56911EN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P69032B56911EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970